Conrad Xiamen Awarded Four-Star Recognition in the 2025 Forbes Travel Guide
The Only Forbes-Starred Hotel in Xiamen XIAMEN, China, Feb. 13, 2025 /PRNewswire/ -- Conrad Xiamen proudly announces its Four-Star recognition in the 2025 Forbes Travel Guide, making it the only hotel in Xiamen to receive this prestigious accolade....
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases,...
Databricks Announces Launch of SAP Databricks
Databricks announces new product natively integrated into the SAP Business Data Cloud SAN FRANCISCO, Feb. 13, 2025 /PRNewswire/ -- Databricks, the Data and AI company, today announced the launch of SAP Databricks, a strategic product and...
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market...
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients. TOKYO, Feb. 13, 2025 /PRNewswire/ -- Restore...
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug...
Illuccix® Approved in the United Kingdom
MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the...
Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that...
IFS named a Leader in two IDC MarketScape 2024-2025 Vendor Assessments: Manufacturing ERP and Remanufacturing Management Software
LONDON, Feb. 12, 2025 /PRNewswire/ -- IFS, the leading enterprise cloud and Industrial AI software provider, announces that it has been positioned as a Leader in two IDC MarketScape reports: the IDC MarketScape: Worldwide SaaS and Cloud-Enabled...
ZIWIG ENDOTEST®: FAST-TRACK REIMBURSEMENT FOR 25 000 PATIENTS FOR FIRST SALIVA TEST TO DIAGNOSE ENDOMETRIOSIS IN 80 MEDICAL CENTERS IN FRANCE
LYON, France, Feb. 11, 2025 /PRNewswire/ -- Ziwig, a French biotech company committed to advancing women's health, announces the fast-track reimbursement of Ziwig Endotest® - the first saliva diagnostic test for endometriosis- for 25 000 patients...